Announcements Trials
Browse Landscape

Phase

Phase 2 32Phase 1 6Phase NA 4Phase 1/2 3Phase 3 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 10OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1Castration-resistant Prostate Cancer 1Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × abiraterone × Clear all
NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Thomas Jefferson University

Phase 1/2 Completed
9 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT01780220 2022-05-19

CARLHA

UNICANCER

Phase 1/2 Completed
47 enrolled
Genitourinary

Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy

NCT04839055 2021-04-09

CoA-CRPC

Jiangnan University

Phase 1/2 Unknown
50 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡